Literature DB >> 21251952

HT-29 colorectal cancer cells undergoing apoptosis overexpress COX-2 to delay ursolic acid-induced cell death.

Youness Limami1, Aline Pinon, David Yannick Leger, Yoanne Mousseau, Jeanne Cook-Moreau, Jean-Louis Beneytout, Christiane Delage, Bertrand Liagre, Alain Simon.   

Abstract

Colorectal cancer is one of the most common cancer types and the third leading cause of cancer-related death in the western world. Generally, colorectal cancers are resistant to anticancer drugs. Several lines of evidence support a critical role for cyclooxygenase-2 (COX-2) during colorectal tumorigenesis and its role in chemoresistance. In this study, we focused our interest on the role played by COX-2 in apoptosis induced in HT-29 human colorectal cancer cells by ursolic acid (UA), a triterpenoid found in a large variety of plants. We showed that UA-induced apoptosis and that COX-2 was overexpressed only in apoptotic cells. We demonstrated that this overexpression was mediated by the p38 MAP kinase pathway as inhibiting its activation using a p38-specific inhibitor, SB 203580, abrogated COX-2 expression. Inhibiting COX-2 expression either by using a p38-specific inhibitor or COX-2-specific siRNA increased apoptosis. These results demonstrated that COX-2 was involved in a resistance mechanism to UA-induced apoptosis in HT-29 cells. Cells undergoing apoptosis were able to trigger a resistance mechanism by overexpressing a protein such as COX-2 to delay their death. Furthermore, we demonstrated that this resistance mechanism was independent of PGE(2) production as the addition of the specific COX-2 activity inhibitor, NS-398, did not affect apoptosis in UA-treated cells.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21251952     DOI: 10.1016/j.biochi.2011.01.003

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  8 in total

1.  Reviewing the role of P2Y receptors in specific gastrointestinal cancers.

Authors:  Steve Dagenais Bellefeuille; Caroline M Molle; Fernand-Pierre Gendron
Journal:  Purinergic Signal       Date:  2019-09-02       Impact factor: 3.765

Review 2.  p38α MAPK pathway: a key factor in colorectal cancer therapy and chemoresistance.

Authors:  Valentina Grossi; Alessia Peserico; Tugsan Tezil; Cristiano Simone
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

3.  Resveratrol and P-glycoprotein inhibitors enhance the anti-skin cancer effects of ursolic acid.

Authors:  Jacob J Junco; Anna Mancha; Gunjan Malik; Sung-Jen Wei; Dae Joon Kim; Huiyun Liang; Thomas J Slaga
Journal:  Mol Cancer Res       Date:  2013-09-26       Impact factor: 5.852

Review 4.  Research progress of ursolic acid's anti-tumor actions.

Authors:  Li-li Zang; Bao-ning Wu; Yuan Lin; Jun Wang; Lei Fu; Ze-yao Tang
Journal:  Chin J Integr Med       Date:  2013-12-29       Impact factor: 1.978

5.  Efficient delivery of ursolic acid by poly(N-vinylpyrrolidone)-block-poly (ε-caprolactone) nanoparticles for inhibiting the growth of hepatocellular carcinoma in vitro and in vivo.

Authors:  Hao Zhang; Donghui Zheng; Jing Ding; Huae Xu; Xiaolin Li; Weihao Sun
Journal:  Int J Nanomedicine       Date:  2015-03-11

Review 6.  Important roles of P2Y receptors in the inflammation and cancer of digestive system.

Authors:  Han-Xing Wan; Jian-Hong Hu; Rei Xie; Shi-Ming Yang; Hui Dong
Journal:  Oncotarget       Date:  2016-05-10

7.  The effects of ursolic acid on cytokine production via the MAPK pathways in leukemic T-cells.

Authors:  Narawan Kaewthawee; Sirikalaya Brimson
Journal:  EXCLI J       Date:  2013-02-08       Impact factor: 4.068

8.  Cyclooxygenase-2 mediated synergistic effect of ursolic acid in combination with paclitaxel against human gastric carcinoma.

Authors:  Xian Xu; Guo-Qin Zhu; Kai Zhang; Yi-Chan Zhou; Xiao-Lin Li; Wei Xu; Hao Zhang; Yun Shao; Zhen-Yu Zhang; Wei-Hao Sun
Journal:  Oncotarget       Date:  2017-10-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.